Format

Send to:

Choose Destination

Links from

Full record GDS5420

Psoriasis response to brodalumab: dose response and time course

Analysis of non-lesional and lesional psoriatic skins for up to 43 days following treatment with various doses of brodalumab, a human IgG2 mAb that selectively binds and blocks signaling through IL-17RA. Results provide insight into the molecular effect of blocking IL-17 signaling in psoriatic skin.
Organism:
Homo sapiens
Type:
Expression profiling by array, count, 3 agent, 4 dose, 25 individual, 4 time, 2 tissue sets
Platform:
GPL570
Series:
GSE53552
99 Samples
Download data: CEL
DataSet
Accession:
GDS5420
ID:
5420

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center